H.U. GROUP HOLDINGS INC.
History
| Year | Detail |
|---|---|
| 1950 | H.U. Group Holdings, Inc. was incorporated in 1950 and was initially founded as Fujizoki Pharmaceutical. |
| 2018 | Fujirebio Inc., a subsidiary of Miraca Holdings Inc., collaborated with Janssen Pharmaceuticals to develop and commercialize the AMYLOID β 42/40 RATIO assay, which helps identify patients who benefit from treatment with Janssen's oral BACE inhibitor, atabecestat. |
| 2022 | H.U. Group Holdings Inc. acquired Fluxus, a Silicon Valley-based biotechnology company, to accelerate the development of ultra-high sensitivity detection technology. |
| 2023 | Fujirebio and Sysmex collaborated on research and development, production, clinical development, and sales-marketing in the immunoassay field. |
| 2024 | Fujirebio partnered with Abbott to develop a research-use-only (RUO) Neurofilament Light chain (Nf-L) assay for Abbott’s Alinity i. |
| 2025 | Fujirebio acquired Plasma Services Group Inc. to strengthen its position as a provider of biological raw materials to the IVD and life science industries. |
BCC Research Beacon 